- Existing-Home Sales Jump to 2-1/2 Year High
- Wave of Debt Payments Facing US Government
- US Job Losses to Bottom out Next Quarter: NABE
- Obama Jobs Forum May Be More Political Than Practical
- Late Payments on Credit Cards Drop in Third Quarter
- Suze Orman’s 'A Healthier, Wealthier You'
- Latest Holiday Drinks: The Madoff...and the TARPatini
- Madoff Trustee, Law Firm Submit $22.1 Million Bill
- JPMorgan's Dimon Could Succeed Geithner: Report
- Expect a 'Square Root-Shaped' Recovery: Chief Investor
- Madoff—The Holiday Drink
- HP to Feed on Enterprise Spending Next Year: Tech Analyst
- Busch: Markets Smell a Country Rat
- Schork Oil Outlook: Mission Impossible For The Bears?
- S&P Stocks Trading at New 52-Week Highs
- Losey: Asset Allocation At Retirement
- Farrell: Obama Hectored, Ignored and Restricted?
- Don't Dwell on Investment Mistakes; Move on, Like Buffett
MOST SHARED
- Existing-Home Sales Jump To Highest Level in 2-1/2 Years
- Wall Street Finds Profits by Reducing Mortgages
- Start-Up Proves Everything Really Is Better With Bacon
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
- Wave of Debt Payments Facing US Government
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Cadbury Hits New High as Bidders Circle
- China Asks Its Banks to Slow Down
Text Size 
The chief executive of Schering-Plough [SGP
Loading...
()
] told CNBC that the drug company's latest earnings are a further sign that a three-year-old restructuring is having a positive impact.
"We are going into this year with momentum, we are growing very nicely on the top line, we're exerting financial discipline, and our bottom line is growing faster than our top line," CEO Fred Hassan said in an appearance on "Power Lunch" on Monday. "That's a great strategy to have."
The company announced fourth-quarter earnings Monday morning in-line with Wall Street expectations.
"What's very, very good is to see that this company--that was in dire straits three-and-a half years ago--has had its first three years of a strategic plan come through beautifully," Hassan added. "We're a much stronger company than we were three-and-a half years ago."
The company, based in Kenilworth, N.J., reported an adjusted profit of 17 cents per share on sales of $2.7 billion, compared with the Thomson Financial consensus forecasts of 17 cents and $2.53 billion, respectively.
Schering-Plough, which co-markets cholesterol drug Vytorin with Merck [MRK
Loading...
()
], logged $1.1 billion in sales of cholesterol drugs in the quarter. Sales of arthritis drug Remicade rose 34% from the year-ago period to $337 million.
James Kelly of Goldman Sachs raised the price target on the stock to $28 from $25 but said the company will need to find new areas of growth as sales of cholesterol drugs Vytorin and Zetia cool off.
"Schering-Plough’s key strategic challenge is diversification of the revenue base, away from the cholesterol franchise," Kelly wrote in a research report sent to clients on Monday.
"The growth of Nasonex and Remicade are important avenues of diversification, and we will watch the impact of new competition on these franchises."
Merrill Lynch's David Risinger expressed a similar sentiment, saying investor attention will be closely focused on the slowdown in the cholesterol drug market.
"Cholesterol market new prescription growth has been cut in half recently, to approximately 6% to 7% year-over-year growth in the last three weeks versus 13% growth in full-year 2006," Risinger said.
Print
Email
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- The show attracts a big TV audience every year, but this year it may take on even more importance.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- A Macau casino will open Asia's first Michael Jackson shrine after its owners made a key purchase at a US auction.
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes